Invivyd's Covid antibody alternative advances, FDA hurdle looms

Invivyd's injectable monoclonal antibody for Covid prophylaxis shows progress, but an FDA regulatory hurdle may delay approval. The development is a company-specific milestone with uncertain market impact.